“We believe this combination uniquely positions Vertos for significant
growth and will provide a healthy return on our investment,” continues
Ryan.
Approximately 900,000 Americans undergo some type of
treatment for LSS every year involving pain medications or steroid
injections, but these treatments tend to wear off or lose effectiveness
over time. Many patients are not considered appropriate candidates for
traditional invasive back surgery. Mild offers an alternative
image-guided procedure, performed through a portal that is smaller than
the diameter of a pencil.
“This sizeable financing is an
important milestone for Vertos and demonstrates recognition of the
market potential of our Mild procedure,” says James Corbett, president
and CEO of Vertos. “We are grateful to have the backing of high-caliber
venture partners, including ONSET Ventures, as we endeavor to bring the
mild solution to physicians and patients across the country.”